The most common severe interactions were between acetylsalicylic acid (ASA)-angiotensin-converting-enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs)-diuretics (n = 29; reduced antihypertensive effect, deterioration in kidney function), potassium chloride-ACE inhibitors/ARBs (n = 7; risk for hyperkalemia), ASS-metamizole (n = 5; reduction of antiplatelet effect), ASS-antidepressants (n = 5; risk of gastrointestinal bleeding) and ACE inhibitors/ARBs-potassium-sparing diuretics (n = 3; risk for hyperkalemia). Here, ACE is linked to Hyperkalemia.